tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of James Quigley, 29 are a HOLD (61.7%), 14 are a BUY (29.79%), 4 are a SELL (8.51%).
Analyst James Quigley, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 54.1% that have a potential upside of 30.47% achieved within 172 days.
James Quigley’s has documented 87 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NVO, Novo Nordisk A/S at 28-Nov-2025.
Analyst best performing recommendations are on KYMR (KYMERA THERAPEUTICS).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/13/2023. The price target of $24 was fulfilled within 30 days with a profit of $9.02 (60.21%) receiving and performance score of 20.07.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Jun-2023
$17
$-1.96 (-10.34%)
$17
1 years 11 months 26 days ago
(05-Feb-2024)
3/3 (100%)
$-0.27 (-1.56%)
96
Hold Since 16-Jan-2024
$9.2
2 years 15 days ago
(16-Jan-2024)
4/10 (40%)
$2.7 (41.54%)
490
Buy Since 16-Jun-2023
$8.5
$-10.46 (-55.17%)
$10
2 years 1 months 26 days ago
(05-Dec-2023)
3/7 (42.86%)
$0.92 (12.14%)
253
Buy Since 16-Jun-2023
$8.5
$-10.46 (-55.17%)
$10
2 years 1 months 26 days ago
(05-Dec-2023)
2/2 (100%)
$0.92 (12.14%)
106
Hold
$4.75
$-13.1 (-73.39%)
2 years 2 months 9 days ago
(22-Nov-2023)
1/2 (50%)
$0.2 (4.40%)
5
Which stock is James Quigley is most bullish on?
Which stock is James Quigley is most reserved on?
What Year was the first public recommendation made by James Quigley?
